Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with Sarepta (SRPT) for multiple TRiM programs for $500M cash upfront, $325M equity investment, $250M to be paid over 5 years, up to $10B in total milestones, plus low double-digit royalties.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARWR:
- Sarepta price target lowered to $182 from $200 at Piper Sandler
- Arrowhead price target lowered to $26 from $27 at Citi
- Arrowhead Pharmaceuticals Eyes Future Growth with Strategic Deals
- Closing Bell Movers: Ambarella surges after earnings
- Arrowhead reports FY24 EPS ($5.00), consensus ($4.53)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
